Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Latest presentations
Analyst reports
Investment thesis
Latest CEO Comments
JULY 15, 2021
"First commercial DTx contract signed
with a large healthcare provider"
Read the latest CEO comments from Nikolaj Sørensen
News flow
Press Releases and News
Synthetic opioids drive record-high surge in fatal overdoses
Orexo’s flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo
Key financial figures
Group net revenue
585 MSEK
Last Twelve Months, Q320-Q221
Group EBITDA
-76 MSEK
Last Twelve Months, Q320-Q221
US Pharma segment EBIT
295 MSEK
Last Twelve Months, Q320-Q221
Cash position
680 MSEK
Q221
